You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead’s U.S. Advancing Access® program provides assistance to patients in the United States who do not have insurance or who need financial assistance.
As part of this program, Gilead provides assistance for people who cannot afford to pay for Viread® (tenofovir disoproxil fumarate) for the treatment of HIV and chronic hepatitis B; Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Emtriva® (emtricitabine) for the treatment of HIV; Hepsera® (adefovir dipivoxil) for the treatment of chronic hepatitis B; Vistide® (cidofovir injection), a treatment for cytomegalovirus retinitis in patients with AIDS and Stribild® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg).
To find out if you are eligible for this patient assistance program, contact Advancing Access at 1-800-226-2056 between 9:00 a.m. and 8:00 p.m. (Eastern).